Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?
Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?
复制标题
DOI：
10.1111/liv.13673
复制
发表时间：
2018-02-01
影响因子：
6.7
通讯作者：
Schinazi, Raymond F.
中科院分区：
文献类型：
--
作者：
Asselah, Tarik;Marcellin, Patrick;Schinazi, Raymond F.
全世界约有7100万人慢性感染丙型肝炎病毒。丙型肝炎病毒抗病毒药物的发展是显著的。具有优异疗效和良好耐受性的泛型直接作用抗病毒药物的可用性为在世界范围内消除丙型肝炎病毒提供了独特的机会。在8-12周的治疗后，不含干扰素的DAA组合现在可以治愈95%以上的HCV感染患者。消除丙型肝炎病毒的规划必须包括加强筛查（基于风险的和普遍的）、与保健的联系以及在世界范围内增加获得治疗的机会。在本文中，我们将回顾最近批准的直接作用抗病毒药物的现有数据，这些药物的持续病毒学反应几乎达到100%。
Around 71 million people are chronically infected with HCV worldwide. HCV antiviral drug development has been remarkable. The availability of pangenotypic direct-acting antivirals with excellent efficacy and good tolerability profiles offer a unique opportunity to achieve HCV elimination worldwide. IFN-free DAA combinations can now cure HCV in more than 95% of patients with HCV infection after 8-12weeks of treatment. Programmes to eliminate HCV must include increased screening (risk-based and universal), linkage to care, as well as increased access to treatment worldwide. In this paper, we will review the available data on recently approved direct-acting antiviral agents, with sustained virological response that reaches almost 100%.